If the share consolidation proposal is approved at the annual meeting, it will be good for the future SNTI. The accumulated deficit was around $67M till the most recent quarter. Thus, the investors, mainly the owners / managers who have funded the company so far, will look to recover their share of investment. Perhaps, this is the reason equity funding is planned in a bigger way by listing on exchanges. Management is non-committal on this so far but that is perhaps the way forward. Whether it is success during further research on anti-cancer drug candidate SNS01-T or agricultural research for enhancement of crop yield, the potential definitely exists. For example, cure for multiple myeloma, non-Hodgkin B-cell lymplomas and inflammatory conditions / ischemic diseases does have a huge market. In addition this particular drug also has potential uses in other indication based on its intrinsic ability to induce or inhibit programmed cell death. The problem is that the stock is at all time lows and hence people are worried about the future. But management is trying to monetize its potential through equity funding. The costing of operations is efficient with most of the research work outsourced to scientists in labs of educational institutions (viz. University of Waterloo). Payments are based on the basis of actual expenditure. Furthermore, the talent of these Universities is accessed at no cost. In addition, the institutions will pay SNTI in case of successful discoveries. As mentioned in the proxy, a lot of executive compensation is affected through stock options which reduces the cash requirement. Thus, at the current price of $0.09, one can consider buying the stock purely based on the future potential of monetization of its IPR in cancer / agriculture related research and the prospects of equity funding in the near future. The recent equity financing of $2M was at price of around $0.10. Thus some sort of rebound can be expected within the next few days.
There is only one thing that will be good for the future of SNTI, that is the quick completion of the 2nd, 3rd, and 4th cohorts. That is where managements focus should be, not on this consolidation BS, that is a joke. Consolidation is useless if these cohorts continue to drag out like they are now. It has been 1 1/2 years and they have completed only 1 cohort. If they keep dragging out the cohorts the only thing consolidation and more dilution will do is let an outsider buy this tech cheap on a takeover.
lololololol What the f was that?
I think we all know the science works and will create significant wealth...however, this management team has failed miserably at getting the share price to reflect this. Les Brown took Bruce Galtons presentation and has been saying the same thing over and over. It took him almost a year before he realized how important this science is.
Ive had him on several calls...he does not inspire any buying and excitment about its potential.
Sadly, it may take another 18 months and likely have to give away another 70% of the company for cash to get through the first phase, and the science (due soley by John Thompson) will prove its worth. Management will hang their hat on it despite any monkey being able to do what they have done.
Good Luck on the AG side...you are very new!
Im still very bullish on the science, but managements inability to raise money, promote the stock, and structure clinical trials has cost all of us time and money. (Its a biotech, that should have been 70% of their job)
As for your comment on the stock making a come back. You must be connect to the promoter that took down the stock. Your team has got a lot of PR, however, management has done nothing to support it. not to mention, the initial shares from the financing were probably sold to recoup the capital. Any futher PR will be for his warrants. If you guys were smart you would save your bullets for when management decides to issue a press release.
Do not come onto this baord with such B$.
management has failed, unfortunately the baord has no alternatives. It took Les a year to buy into the story (Im basing this on a comment he made last summer, he finally stated that he has never felt so strong about the science).
If this company reverses splits the stock, our next financing will be at 5 cents (presplit equivalent). Unless the science surprises even our expecations on the trial.
p.s. management has barely (it at all) put a dime into this compnay. Only the Baord.
This is a great summary, company like this developing stage, all money should be allocated to R&D - JT, keep admin cost as nil, the only way admin staff gets paid is to film a "pay-per-view" movie on the Youtube, so that additional cash inflow will create PR and fund all supporting functions. The funny thing is that they repeated those slides for 3 years during investment seminars. If they had the confidence, starting the cure process else to force XDA approval instead of begging them. The shocking part is to train a CEO who has a totally different educational background and a very "inbox" thinker, totally wasted time and money.
As I said before, the admin office should be located in Hollywood to make $$ in movie instead of NJ where flooding with these cheap shares to pollute the financial health of the company.
Conclusion, a stealth CEO with minimum BS and clear mandate/deadlines should restore the vibe of this company, of course, the choice for this CEO should 0% pay increse or 500% pay increase. NO 4%.
I have heard everything you've said several times in other stocks, and it never worked. Reversing this from .09 cents to $1.80 in theory solves a lot of problems, but when it quickly drops back to .20 cents you now have an irreversible disaster, with all the original problems magnified by 20. My guess is you have never been involved in a reverse split or you would be singing a different tune.
You are obviously in the winter wonderland. The reversee split and management retention tells you nothing is bullish here. I wish I did not put a dime in this company despite the fact there is a world class discovery offset by world class financial cancer - share dilution from 34 million to 260 million in less 3 years. Good luck with your fantsy.